| Abstract: |
High-grade gliomas (HGGs) in children and adults represent a clinically and biologically diverse group of tumor entities, the majority of which are characterized by diffusely infiltrative and rapid growth, limited responsiveness to radiation and chemotherapy, and very poor outcome. Recent advances in central nervous system tumor genomics have led to significant progress in our understanding of tumor biology and classification, allowing for more precise diagnosis, improved prognostication, and in some instances, successful treatment with molecular targeted therapies and immunotherapies. Nevertheless, the prognosis for the vast majority of pediatric patients with HGGs remains dismal, and novel; more effective therapeutic approaches are needed to improve outcomes in the future. © 2025 Elsevier B.V., All rights reserved. |
